NCT00924027 2025-09-05A Study of Patients Receiving High-Dose Rate BrachytherapyNational Institutes of Health Clinical Center (CC)Phase 2 Completed43 enrolled 13 charts
NCT02443324 2024-07-31A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerEli Lilly and CompanyPhase 1 Completed175 enrolled 23 charts
NCT02091141 2024-07-23My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsGenentech, Inc.Phase 2 Completed673 enrolled 22 charts